Xention spins out overactive bladder programme
This article was originally published in Scrip
Executive Summary
Xention (UK), which is focused on the discovery and development of ion channel-modulating drugs, has spun out its overactive bladder (OAB) programme into a newly established company, Provesica, separately owned by Xention's shareholders.